Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 23, 2026Sponsor estimate | NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · Chickenpox | GSKLead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Nov 24, 2026Sponsor estimate | NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Alzheimer Disease | BMYLead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Nov 29, 2026Sponsor estimate | NCT06641466A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigrainePfizer · Menstrual Migraine | PFELead | Phase 3 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 23, 2026Sponsor estimatePhase 3NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2026Sponsor estimatePhase 3NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Alzheimer DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2026Sponsor estimatePhase 3NCT06641466A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigrainePfizer · Menstrual MigraineRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT05065216Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)DiaMedica Therapeutics Inc · Acute StrokeRecruitingDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in...Genelux Corporation · Platinum-resistant Ovarian CancerRecruitingGNLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06274801Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)Gossamer Bio USA, Inc. · Pulmonary Arterial HypertensionRecruitingGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06413433Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolAxsome Therapeutics, Inc. · Binge-Eating DisorderRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06568367Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)Axsome Therapeutics, Inc. · Excessive SleepinessRecruitingAXSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06568627A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)MediWound Ltd · Venous Leg Ulcer (VLU)RecruitingMDWDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07016750A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaKrystal Biotech, Inc. · Dystrophic Epidermolysis BullosaRecruitingKRYSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07019922A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyPraxis Precision Medicines · Epileptic EncephalopathyRecruitingPRAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 3NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseVanda Pharmaceuticals · Nausea and VomitingRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2026Sponsor estimatePhase 3NCT07500506A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePfizer · Lyme DiseaseRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2026Sponsor estimatePhase 3NCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Psychosis Associated With Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 3NCT06806137A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3...GlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2/Phase 3NCT05327114Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Janssen Research & Development, LLC · Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 3NCT06607627PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc. · Generalized Myasthenia GravisRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 25, 2026Sponsor estimatePhase 3NCT06740630A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2026Sponsor estimatePhase 3NCT07645248A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and...GlaxoSmithKline · AsthmaRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2/Phase 3NCT05789056Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT06559306Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia...Janssen Research & Development, LLC · Depressive Disorder, MajorRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2/Phase 3NCT06953466Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT06104566Global Trial in APG2575 for Patients With CLL/SLLAscentage Pharma Group Inc. · CLL/SLLRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT07505836Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsSinovac Biotech Co., Ltd · Epidemic Meningitis | SVALead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Jan 7, 2027Sponsor estimate | NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi · Sickle Cell Disease | SNYLead | Phase 3 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 3NCT07505836Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsSinovac Biotech Co., Ltd · Epidemic MeningitisRecruitingSVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2027Sponsor estimatePhase 3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi · Sickle Cell DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 8 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.